ERNA — Ernexa Therapeutics Share Price
0.000.00%
Last trade - 00:00- $12.59m
- $10.86m
- $0.58m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.41 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 21.63 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1635.09% | ||
| Return on Equity | -2266.28% | ||
| Operating Margin | -6548.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.8 | n/a | n/a | 0.07 | 0.58 | n/a | n/a | -50.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Directors
- Allen Wolff CHM (49)
- Lynn Mason EVP (42)
- Jay Sial CAD (57)
- Kevin D' Amour CSO (48)
- Sandra Gurrola VFN (54)
- Ronald Guido OTH (62)
- Roger Sidhu OTH (45)
- Charles Cherington IND (57)
- Erin Enright IND (60)
- Dennis Langer IND (69)
- Erich Mohr IND (66)
- Heather Redman IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 13th, 1984
- Public Since
- August 29th, 1991
- No. of Shareholders
- 146
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 62,178,945
- Address
- 1035 Cambridge Street, Suite 18A, CAMBRIDGE, 02141
- Web
- https://www.ernexatx.com/
- Phone
- +1 6177986700
- Auditors
- Grant Thornton LLP
Upcoming Events for ERNA
Ernexa Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Eterna Therapeutics Inc Earnings Release
Similar to ERNA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Ernexa Therapeutics share price?
As of Today at 20:30 UTC, shares in Ernexa Therapeutics are trading at $0.20. This share price information is delayed by 15 minutes.
How has the Ernexa Therapeutics share price performed this year?
Shares in Ernexa Therapeutics last closed at $0.20 and the price had moved by -88.16% over the past 365 days. In terms of relative price strength the Ernexa Therapeutics share price has underperformed the S&P500 Index by -89.32% over the past year.
What are the analyst and broker recommendations for Ernexa Therapeutics?
The overall consensus recommendation for Ernexa Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Ernexa Therapeutics dividend yield?
Ernexa Therapeutics does not currently pay a dividend.
Does Ernexa Therapeutics pay a dividend?
Ernexa Therapeutics does not currently pay a dividend.
When does Ernexa Therapeutics next pay dividends?
Ernexa Therapeutics does not currently pay a dividend.
How do I buy Ernexa Therapeutics shares?
To buy shares in Ernexa Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ernexa Therapeutics?
As of the previous close price of $0.20, shares in Ernexa Therapeutics had a market capitalisation of $12.59m.
Where are Ernexa Therapeutics shares listed?
Here are the trading details for Ernexa Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ERNA
What kind of share is Ernexa Therapeutics?
Based on an overall assessment of its quality, value and momentum Ernexa Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ernexa Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Ernexa Therapeutics is $3.00. That is 1381.48% above the last closing price of $0.20.
Analysts covering Ernexa Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Ernexa Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ernexa Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -80.44%.
As of the last closing price of $0.20, shares in Ernexa Therapeutics were trading -74.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ernexa Therapeutics PE Ratio?
The Ernexa Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ernexa Therapeutics?
Ernexa Therapeutics' management team is headed by:
- Allen Wolff - CHM
- Lynn Mason - EVP
- Jay Sial - CAD
- Kevin D' Amour - CSO
- Sandra Gurrola - VFN
- Ronald Guido - OTH
- Roger Sidhu - OTH
- Charles Cherington - IND
- Erin Enright - IND
- Dennis Langer - IND
- Erich Mohr - IND
- Heather Redman - IND